Houston-area health care providers see rising demand for diabetes, obesity drugs
A new request by Ozempic manufacturer Novo Nordisk could limit the availability of a type of GLP-1—semaglutides—to local clinics and pharmacies. This shift comes amid safety concerns regarding compounded versions of the drugs and could cause price increases, medical professionals say.
